

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Protomix Corporation Limited	12/02/2010
RECEIVING PARTY DATA	
Name:	Phileria New Zealand Limited
Street Address:	2 Crummer Road, Grey Lynn
City:	Auckland
State/Country:	NEW ZEALAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13269399
CORRESPONDENCE DATA	
Fax Number:	(312)913-0002
Phone:	312-913-0001
Email:	neth@mbhb.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	McDonnell Boehnen Hulbert & Berghoff LLP
Address Line 1:	300 South Wacker Drive
Address Line 4:	Chicago, ILLINOIS 60606
ATTORNEY DOCKET NUMBER:	11-511-US-CON
NAME OF SUBMITTER:	Michael S. Greenfield
Total Attachments: 10 source=11_511_US_CON_ProtomixToPhileriaAssign#page1.tif source=11_511_US_CON_ProtomixToPhileriaAssign#page2.tif source=11_511_US_CON_ProtomixToPhileriaAssign#page3.tif source=11_511_US_CON_ProtomixToPhileriaAssign#page4.tif source=11_511_US_CON_ProtomixToPhileriaAssign#page5.tif	

CH \$40.00 13269399

501689132

PATENT
REEL: 027051 FRAME: 0894

source=11_511_US_CON_ProtmixToPhilerAssign#page6.tif
source=11_511_US_CON_ProtmixToPhilerAssign#page7.tif
source=11_511_US_CON_ProtmixToPhilerAssign#page8.tif
source=11_511_US_CON_ProtmixToPhilerAssign#page9.tif
source=11_511_US_CON_ProtmixToPhilerAssign#page10.tif

PROTEMIX CORPORATION LIMITED
(IN LIQUIDATION)

PHILERA NEW ZEALAND LIMITED

DEED OF ASSIGNMENT OF
INTELLECTUAL PROPERTY RIGHTS

PARTIES

PROTEMIX CORPORATION LIMITED (IN LIQUIDATION), a New Zealand company whose registered office is located at Level 5, 57 Fort Street, Auckland, New Zealand ("Assignor")

PHILERA NEW ZEALAND LIMITED, a New Zealand company whose registered office is located at 2 Crummer Road, Grey Lynn, Auckland, New Zealand ("Assignee")

INTRODUCTION

- A. The Assignor acknowledges that the Assignee is or should be the legal and beneficial owner of the Intellectual Property Rights.
- B. To the extent that the Assignor still has any Intellectual Property Rights, the Assignor has agreed to assign, and the Assignee has agreed to accept, such Intellectual Property Rights subject to the terms and conditions of this deed.

COVENANTS

1. DEFINITIONS

- 1.1 In this deed, including the Introduction, the following words will have the following meanings:

"Copyright" means all copyrights and all rights in the nature of copyright, in any original artistic, literary and other works comprising or relating to the Inventions as may exist anywhere in the world;

"Design Rights" means all rights in and to the designs to be applied to articles of or relating to the Inventions as may exist anywhere in the world including, but not limited to:

- (a) the right to apply for and obtain protection for such designs in relation to such articles and the rights conferred by such protection when granted;
- (b) the right to claim priority under any international convention or agreement including the Paris Convention (as amended) from any such application or applications referred to in paragraph (a) above;
- (c) any unregistered design rights; and
- (d) any semi-conductor topography or integrated circuit layout rights;

"Intellectual Property Rights" means all industrial and intellectual property rights (whether protectable by statute, at common law or in equity) in and to the Inventions as may exist anywhere in the world and whether or not registered or registrable including, but not limited to, the Patent Rights, Copyright and Design Rights;

"Inventions" means any and all inventions the subject of the Patents;

"Patents" means the patents and patent applications identified in the Schedule; and

mc
A

"Patent Rights" means all patent rights in and to the Inventions as may exist or come into existence anywhere in the world including, but not limited to:

- (a) the right to apply for and obtain patents or other similar forms of protection in respect of the Inventions in any country;
- (b) the right to claim priority under any international convention or agreement including the Paris Convention (as amended) from any such application or applications referred to in paragraph (a) above;
- (c) all rights conferred by any such patent(s) or similar forms of protection when granted; and
- (d) the Patents together with:
 - (i) any patents that may be granted pursuant to the Patents; and
 - (ii) any future patent(s) and patent application(s) that are based on or derive priority from or have equivalent claims to the Patents in any country in the world (including divisionals, continuations, continuations in part, supplementary protection certificates, reissues, extensions, innovation patents and petty patents).

2. ASSIGNMENT

- 2.1 **Assignment:** The Assignor hereby assigns to the Assignee absolutely all of the Assignor's rights, title and interest in and to the Intellectual Property Rights.
- 2.2 **Rights of action:** The assignments effected by clause 2.1 include, without limitation, the assignment and transfer of all rights of action, powers and benefits arising from the ownership of the Intellectual Property Rights including, without limitation, the right to sue for damages and other legal and equitable remedies in respect of all causes of action arising before, on or after the date of this deed.

3. FURTHER ACTIONS

- 3.1 If requested by the Assignee the Assignor will, at the Assignee's expense, execute all documents, give such assistance and do all other acts and things as may be necessary or desirable to give effect to the assignment in this deed and to enable the Assignee to prosecute, maintain, renew, enforce and defend the Intellectual Property Rights.

4. GENERAL

- 4.1 **Waiver:** No failure or delay by any party in exercising any right, power or privilege under this deed will operate as a waiver of such right, power or privilege, nor will any single or partial exercise preclude any other or further exercise of any right, power or privilege under this deed.
- 4.2 **Facsimile counterparts:**
 - (a) This deed may be executed in any number of counterparts (including facsimile copies) all of which, when taken together, will constitute one and the same instrument.


ms
A

- (b) A party may enter into this deed by executing any counterpart. The parties acknowledge that this deed may be executed on the basis of an exchange of facsimile copies and confirm that their respective execution of this deed by such means will be a valid and sufficient execution.

4.3 **Governing law:** The formation, validity, construction and performance of this deed will be governed by and construed in accordance with the laws of New Zealand. The parties irrevocably agree that the Courts of New Zealand will have non-exclusive jurisdiction to hear and determine all disputes under or in connection with this deed. The parties irrevocably waive any objections to New Zealand as the forum for proceedings on the grounds of forum non-conveniens or any similar grounds.

SIGNED AS A DEED

SIGNED by PROTEMIX CORPORATION LIMITED (IN LIQUIDATION) by its liquidator in the presence of:


Signature of liquidator

Date 21/12/10

WITNESS

Signature:


Name:

Address:

Occupation:

Carmen
Carmen Nolens Lottering
Auckland
Administrator

SIGNED by PHILERA NEW ZEALAND LIMITED by:


Signature of Director

MARGARET COOPER
Name of Director

Date

7 DEC 2010

WITNESS

Signature:

Name:

Address:

Occupation:

J. L. Peachey
JOHN PEACHEY.
25 SHIRELAKE CL OXFORD
RETIRED.

SCHEDULE

PATENTS

Patent/Patent Application	Patent/Application Number	Country/Region	Title/Description
Patent Application	2000-571911	Japan	Fructosamine Oxidase: Antagonists And Inhibitors
Patent Application	1818/CHENP/2004	India	Glycoisoforms Of Adiponectin And Uses Thereof
Patent Application	2003-575954	Japan	Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure
Patent Application	432/CHENP/2005	India	A Pharmaceutical Composition Comprising An Acid Addition Salt Of A Copper Chelator And Succinic Acid
Patent Application	719/CHENP/2007	India	Synthesis Of Triethylenetetramines
Patent Application	5184/CHENP/2007	India	A Pharmaceutical Composition Comprising An Acid Addition Salt Of A Copper Chelator And Succinic Acid
Patent Application	2005-535561	Japan	Glycoisoforms Of Adiponectin And Uses Thereof
Patent Application	2003258909	Australia	Dosage Forms And Related Therapies
Patent Application	2496411	Canada	Dosage Forms And Related Therapies
Patent Application	PA/a/2005/002883	Mexico	Dosage Forms And Related Therapies
Patent Application	2003225442	Australia	Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure
Patent Application	2006312407	Australia	Treatment Of Mitochondria-Related Diseases And Improvement Of Age-Related Metabolic Deficits
Patent Application	2344690	Canada	Fructosamine Oxidase Assay: Antagonists And Inhibitors
Patent Application	99946470.4	Europe	Fructosamine Oxidase: Antagonists And Inhibitors
Patent Application	553350	New Zealand	Synthesis Of Triethylenetetramines
Patent Application	2632697	Canada	Treatment Of Mitochondria-Related Diseases And Improvement Of Age-Related Metabolic Deficits
Patent Application	2471833	Canada	Methods And Compositions For Normalising Lipid Levels In Mammalian Tissues

MC

Patent Application	2005312435		Australia	Glyponectin (Glycosylated Adiponectin) For The Treatment Of Diseases And Conditions
Patent Application	2590177		Canada	Glyponectin (Glycosylated Adiponectin) For The Treatment Of Diseases And Conditions
Patent Application	2473781		Canada	Glycoisoforms Of Adiponectin And Uses Thereof
Patent Application	2005281353		Australia	Synthesis Of Triethylenetetramines
Patent Application	03705539.9		Europe	Glycoisoforms Of Adiponectin And Uses Thereof
Patent Application	2478997		Canada	Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure
Patent Application	03744567.3		Europe	Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure
Patent Application	580676		New Zealand	Glyponectin (Glycosylated Adiponectin) For The Treatment Of Diseases And Conditions
Patent Application	2605930		Canada	Copper Regulation Evaluation And Therapy
Patent Application	2006240568		Australia	Copper Regulation Evaluation And Therapy
Patent Application	583976		New Zealand	Copper Regulation Evaluation And Therapy
Patent Application	569027		New Zealand	Treatment Of Mitochondria-Related Diseases And Improvement Of Age-Related Metabolic Deficits
Patent	6897243		USA	Fructosamine Oxidase: Antagonists And Inhibitors
Patent	539272		New Zealand	Fructosamine Oxidase: Antagonists And Inhibitors
Patent	539695		New Zealand	Dosage Forms And Related Therapies
Patent	545724		New Zealand	Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure
Patent Application	00942575.2		EP	Peptide Having Preptin Functionality
Patent Application	02803945.1		EP	Methods of Compositions For Normalizing Lipid Levels In Mammalian Tissues
Patent Application	03792902.3		EP	Dosage Forms And Related Therapies
Patent Application	06824379.9		EP	Treatment Of Mitochondria-Related Diseases And Improvement Of Age-Related Metabolic Deficits
Patent Application	06733173.6		EP	Copper Regulation Evaluation And Therapy
Patent Application	05823200.0		EP	Glyponectin (Glycosylated Adiponectin) For The Treatment Of Diseases And Conditions
Patent Application	05805036.0		EP	Synthesis Of Triethylenetetramines
Patent Application	04808920.5		EP	Copper Antagonist Compounds

Inc

Patent Application	05104473.3	Hong Kong	Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure
Patent Application	05103854.4	Hong Kong	Glycoisofoms And Adiponectin And Uses Thereof
Patent Application	05102413.0	Hong Kong	Methods and Compositions For Normalizing Lipid Levels in Mammalian Tissues
Patent Application	05106292.7	Hong Kong	Dosage Forms And Related Therapies
The schedule entitled External terms report 6/28/2010 that was attached to the liquidators' "Invitation to Tender" letter dated 27 July 2010 sets out items that are all duplicated elsewhere in this schedule. For this reason they have not been included.			
Patent Application	PCT/NZ00/00102	PCT	Peptide Having Preptin Functionality
Patent Application	09/745,078	USA	Peptide Having Preptin Functionality
Patent Application	10/374,624	USA	Peptide
Patent Application	60/400,445	USA	Preptin Methods of Use
Patent Application	PCT/NZ03/00168	PCT	Preptin Methods of Use (Mitogenic Effects of Preptin in Non-Bone Tissues)
Patent Application	10/632,366	USA	Methods of Use of Compounds with Preptin Function
Patent Application	60/333,422	USA	Methods and Compositions for Normalizing Muscle Lipid Levels
Patent Application	PCT/NZ02/00262	PCT	Methods and Compositions for Normalizing Muscle Lipid Levels
Patent Application	10/306,645	USA	Methods and Compositions For Normalizing Lipid Levels in Mammalian Tissue
Patent	772026	Australia	Fructosamine Oxidase: Antagonists And Inhibitors
Patent	6348465	USA	Fructosamine Oxidase: Antagonists And Inhibitors
Patent	6610693 B2	USA	Fructosamine Oxidase: Antagonists And Inhibitors
Patent	7459446	USA	Treatment of Diabetes with Copper Binding Compounds
Patent	6855511	USA	Fructosamine Oxidase Assay: Methods and Materials
Patent Application	PCT/NZ03/00043	PCT	Preventing And/Or Treating Vascular Disease, Cardiomyopathy and Associated Heart Failure
Patent Application	60/364,382	USA	Preventing And/Or Treating Vascular Disease, Cardiomyopathy and Associated Heart Failure
Patent Application	PCT/NZ03/00042	PCT	Preventing And/Or Treating Vascular Disease, Cardiomyopathy and Associated Heart Failure
Patent	6951890	USA	Preventing And/Or Treating Vascular Disease, Cardiomyopathy and Associated Heart Failure
Patent Application	PCT/NZ03/00047	PCT	Preventing And/Or Treating Vascular Disease, Cardiomyopathy and Associated Heart Failure
Patent Application	PCT/NZ03/00184	PCT	Dosage Forms And Related Therapies

SPW

Patent Application	10/525,345	USA	Dosage Forms And Related Therapies
Patent Application	60/531,204	USA	Treatment of Neurodegenerative Conditions
Patent Application	11/018,720	USA	Copper Antagonist Compounds
Patent Application	60/638,062	USA	Improved Medical Devices
Patent Application	60/589,080	USA	Synthesis Of Triethylenetetramines
Patent Application	60/665,521	USA	Copper Antagonist Compositions
Patent Application	60/665,280	USA	Copper Antagonist Compositions
Patent Application	60/665,485	USA	Copper Antagonist Compositions
Patent Application	60/665,522	USA	Copper Antagonist Compositions
Patent Application	60/665,235	USA	Copper Antagonist Compositions
Patent Application	60/665,234	USA	Pre-Complexed Copper Antagonist Compositions
Patent Application	60/665,279	USA	Copper Antagonist Compositions
Patent Application	60/674,734	USA	Copper Regulation Evaluation And Therapy
Patent Application	60/675,310	USA	Copper Regulation Evaluation And Therapy
Patent Application	60/785,944	USA	007-USA-X1 Copper Antagonist Compositions
Patent Application	60/780,584	USA	Phosphoprotein Target For Insulin and its Antagonists
Patent Application	10/964,870	USA	Phosphoprotein target for insulin and its antagonists
Patent Application	PCT/IB02/02488	PCT	Phosphoprotein Target For Insulin and its Antagonists
Patent	523410	New Zealand	Adiponectin and Uses Thereof
Patent Application	523411	New Zealand	Adiponectin and Uses Thereof
Patent Application	60/349,885	USA	Glycoisoforms Of Adiponectin And Uses Thereof
Patent Application	PCT/NZ03/00002	PCT	Adiponectin and Uses Thereof
Patent	7365170	USA	Glycoisoforms Of Adiponectin And Uses Thereof
Patent Application	60/436,178	USA	TNF-Alpha Suppression
Patent Application	60/436,148	USA	Adiponectin and its Antagonists and Uses Thereof
Patent Application	60/625,365	USA	Methods of Treatment

Paul

Patent Application	60/635,044	USA	Methods of Treatment
Patent Application	60/361,152	USA	Low Molecular Weight Adipocyte-Specific Protein Implicated in the Action Insulin
Patent Application	10/378,544	USA	Falp Proteins
Patent Application	PCT/NZ03/00039	PCT	Falp Proteins
Patent Application	516920	New Zealand	Disruption of Islet Amyloid by Polycyclic Compounds
Patent Application	10/354,893	USA	Suppression of Cytotoxic Protein Conformers
Patent Application	PCT/NZ03/00009	PCT	Suppression of Cytotoxic Conformers (Formerly Titled "Disruption of Islet Amyloid by Polycyclic Compounds")
Patent Application	PCT/IB03/06467	PCT	Suppression of Cytotoxic Conformers (Formerly Titled "Disruption of Islet Amyloid by Polycyclic Compounds")
Patent Application	60/376,826	USA	Enzyme with Deglycating Activity
Patent Application	PCT/NZ03/00074	PCT	Proteins with Deglycating Activities and Methods of Using Same (DGE)
Patent Application	533557	New Zealand	Uses and Formulations of N-(O-Carboxybenzoyl) Glutamic Acid Inude and Related Compounds
Patent	7582796	USA	Synthesis Of Triethylenetetramines
Patent Application	60/287,353	USA	Enzyme with Deglycating Activity
Patent Application	60/735,688	USA	Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits
Patent Application	524639	New Zealand	Treatment of Type 2 Diabetes Mellitus (Amylin Immunotherapy)
Patent Application	11/221,298	USA	Preventing And/Or Treating Vascular Disease, Cardiomyopathy and Associated Heart Failure
Patent Application	11/297,169	USA	(013-USA-E2) Methods of Treatment
Patent Application	60/772,451	USA	(007-USA-V1) Triethylenetetramine Salts
Patent Application	60/748,961	USA	(016-USA-B1) Suppression of Cytotoxic Protein Conformers
Patent Application	60/734,654	USA	(013-USA-D2) Methods of Treatment Prv
Patent Application	60/739,728	USA	(007-USA-W3) Treatment of Mitochondria-Related Diseases and Improvement of Age-Related Metabolic Deficits
Patent Application	60/740,799	USA	013-USA-D3-(PRV 3) Methods of Treatment
Patent Application	PCT/IB2005/052421	PCT	Synthesis of Triethylenetetramines

Sub

Patent Application	11/409,495	USA	002-USA-A2 Vesiculatin	
Patent Application	11/412,064	USA	007-USA-U3 Copper Regulation Evaluation Therapy	
Patent Application	10/577,792	USA	(014-USA-A1) Peptides with Anti-Obesity Activity and Other Related Uses	
Patent Application	60/921,721	USA	Modified Adiponectin Proteins	
Patent Application	11/919,051	USA	Copper Regulation Evaluation & Therapy	
Patent Application	11/981,861	USA	Treatment of Diabetes with Copper Binding Compounds	
Patent Application	12/077,040	USA	Divisional - Glycoisoforms Of Adiponectin And Uses Thereof	
Patent Application	12/460,616	USA	(007-USA-M2) of Triethylenetetramines	
Patent Application	11/221,298	USA	Preventing And/Or Treating Cardiovascular Disease And/Or Associated Heart Failure	
Patent Application	11/973,270	USA	Copper Antagonist Compositions	
Patent Application	11/973,271	USA	Copper Antagonist Compositions	
Patent Application	12/077,040	USA	Adiponectin and uses thereof	
Patent Application	12/460,616	USA	Synthesis of triethylenetetramines	
Patent	7365170	USA	Adiponectin and uses thereof	
Patent Application	10577792	USA	Peptides with Anti-Obesity Activity and Other Related Uses	
Patent	6884575	USA	Phosphoprotein Target For Insulin And Its Antagonists	
Patent Application	11297169	USA	Methods of treatment	
Patent Application	12093302	USA	Treatment Of Mitochondria-Related Diseases And Improvement Of Age-Related Metabolic Deficits	
Patent	515722	New Zealand	Peptide (Preptin)	
Patent Application	2004-530685	Japan	Dosage Forms and Related Therapies	
Patent Application	2577634	Canada	Synthesis Of Triethylenetetramines	

